This report will excel your competitive awareness and decrease your decision making time in managing angiogenesis affecting drug development in cancer. Find out whether you are number one, two or further down the ladder in this highly competitive market. Locate the right drugs to benchmark against and see were others may have succeeded or failed before you.

A large number of drugs, both on the market and in development have angiogenesis affecting properties.This report includes both direct angiogenic targets (angiogenesis-related targets) and indirect angiogenic targets (non-angiogenic targets which nevertheless have angiogenesis effects).

This report comprises defined and up to date development strategies for 252 angiogenesis affecting drugs in oncology within the portfolio of 151 companies world-wide, from Ceased to Marketed. The report extensively analyses their 177 identified drug targets, organized into 170 drug target strategies, and assesses them in 70 cancer indications. BioSeeker has applied its unique drug assessment methodology to stratify the angiogenesis affecting drug pipeline in oncology and discern the level of competition in fine detail.

Major Findings from this report:

* The identified competitive landscape of angiogenesis affecting drugs in cancer is split between the half which have unique drug target strategies and the other half which have head-to-head target competing drugs in 44 different clusters. The latter has a competing ratio which is almost two times higher than the comparable average of the angiogenesis affecting drugs in general.

* Eight out of every ten drug target strategies in Phase III development are new to angiogenesis affecting drugs, whereas only five out of every ten target strategies in Phase II are new.

* The greatest number of new target strategies are found in Preclinical (21%) and Phase II (18%) development.

* Small molecules, Antibodies and Proteins drugs are the dominating compound strategies of angiogenesis affecting cancer drugs, which represent almost 80% of the entire pipeline.

* Protein based angiogenesis affecting cancer drugs has the highest cross-over of drug target strategies with other compound strategies, especially with that of Antibodies and Gene therapies.

* Angiogenesis affecting drugs are experiencing targeting competition in five out of every ten cancer indications described, and more so in colorectal cancer, breast cancer and non-small cell lung cancer..

* The highest number of described target strategies among angiogenesis affecting drugs are found in colorectal cancer, breast cancer, non-small cell lung cancer and ovarian cancer.

* The highest number of described drug target strategies of angiogenesis affecting drugs belongs to Pfizer, Novartis, Abbott, Eli Lilly, EntreMed and Exelixis.

The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty. The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:

* Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives

* Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties

* Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities

* Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities

* Supporting development of integrative molecule, pathway and disease area strategies

* Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment

This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any angiogenesis affecting drug in cancer to ensure that the optimal market conditions exist by the time the product is commercialized.

Table Of Contents

1 Executive Summary 3
2 About Cancer Highlightsâ„¢ 5
2.1 Cancer Focus Areas 5
2.2 Subscribe Today and Start Saving 6
2.2.1 Type of License 6
2.3 Additional Information 6
2.4 BioSeeker Group’s Oncology Team 6
3 Methodology 7
3.1 Cancer Highlights’™ Five Pillar Drug Assessment 7
4 Table of Contents 9
4.1 List of Figures 22
4.2 List of Tables22
5 Introduction 37
5.1 The Scope of this Report 37
5.2 Definitions 40
5.3 Abbreviations 40
6 Consider the Therapeutic Target Among Angiogenesis Affecting Drugs in Oncology for the Highest Therapeutic Outcome and Return on Investment 41
6.1 Drug Repositioning in Oncology 41
6.2 Introduction to Targets of Angiogenesis Affecting Drugs in Oncology 42
6.2.1 Calcium Ion Binding Targets 48
6.2.2 Carboxy-lyase Activity Targets 49
6.2.3 Catalytic Activity Targets 51
6.2.4 Cell Adhesion Molecule Activity Targets 56
6.2.5 Chaperone Activity Targets 63
6.2.6 Chemokine Activity Targets 67
6.2.7 Cofactor Binding Targets 69
6.2.8 Cysteine-type Peptidase Activity Targets 71
6.2.9 Cytokine Activity Targets 76
6.2.10 Cytoskeletal Protein Binding Targets 80
6.2.11 DNA Topoisomerase Activity Targets 81
6.2.12 DNA-directed DNA Polymerase Activity Targets 84
6.2.13 Extracellular Matrix Structural Constituent Targets 85
6.2.14 G-protein Coupled Receptor Activity Targets 91
6.2.15 Growth Factor Activity Targets 96
6.2.16 GTPase Activity Targets 112
6.2.17 Hormone Activity Targets 115
6.2.18 Hydrolase Activity Targets 116
6.2.19 Kinase Activity Targets 118
6.2.20 Kinase Binding Targets 121
6.2.21 Lipid Kinase Activity Targets 123
6.2.22 Metallopeptidase Activity Targets 130
6.2.23 Molecular Function Unknown Targets 148
6.2.24 Motor Activity Targets 149
6.2.25 Oxidoreductase Activity Targets 151
6.2.26 Peptidase Activity Targets 153
6.2.27 Phosphoric Diester Hydrolase Activity Targets 169
6.2.28 Protease Inhibitor Activity Targets 172
6.2.29 Protein Binding Targets 176
6.2.30 Protein Serine/Threonine Kinase Activity Targets 180
6.2.31 Protein-tyrosine Kinase Activity Targets 209
6.2.32 Receptor Activity Targets 220
6.2.33 Receptor Binding Targets 245
6.2.34 Receptor Signaling Protein Serine/Threonine Kinase Activity Targets 251
6.2.35 RNA Binding Targets 253
6.2.36 Serine-type Peptidase Activity Targets 254
6.2.37 Structural Constituent of Cytoskeleton Targets 259
6.2.38 Superoxide Dismutase Activity Targets 261
6.2.39 Transcription Factor Activity Targets 264
6.2.40 Transcription Regulator Activity Targets 277
6.2.41 Transferase Activity Targets 284
6.2.42 Translation Regulator Activity Targets 286
6.2.43 Transmembrane Receptor Activity Targets 293
6.2.44 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets 295
6.2.45 Transporter Activity Targets 348
6.2.46 Ubiquitin-specific Protease Activity Targets 352
6.2.47 Unknown Function Targets 353
6.2.48 Voltage-gated Ion Channel Activity Targets 354
6.3 The Cancer Genome Project and Targets of Angiogenesis Affecting Drugs in Oncology 355
6.3.1 Targets of Angiogenesis Affecting Drugs in Oncology Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer 355
6.4 Angiogenesis Affecting Therapeutics is Stimulated by Available Structure Data on Targets 360
6.5 Target-Target Interactions among Identified Targets of Angiogenesis Affecting Drugs in Oncology 364
6.6 The Drug-Target Competitive Landscape 368
6.7 Protein Expression Levels of Identified Targets of Angiogenesis Affecting Drugs in Oncology 372
6.8 Pathway Assessment of Angiogenesis Affecting Drugs in Oncology 375
6.8.1 Tools for Analysis of Cancer Pathways 376
6.8.2 Pathway Assessment 377
7 Emerging New Products to Established Ones: Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology by their Highest Stage of Development 424
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 426
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 428
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 431
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 438
7.5 Preclinical Development: New and Unique Drug Target Strategies of Angiogenesis Affecting Drugs in Oncology 446
7.6 Drug Target Strategies of No Data, Suspended or Terminated Angiogenesis Affecting Drugs in Oncology 450
7.7 Target Strategy Development Profiles of Angiogenesis Affecting Drugs in Oncology 454
7.7.1 Marketed 458
7.7.2 Pre-registration 473
7.7.3 Phase III 477
7.7.4 Phase II 515
7.7.5 Phase I 551
7.7.6 Preclinical 582
7.7.7 Suspended 618
7.7.8 Ceased 619
7.8 The Competition Through Close Mechanistic Approximation of Angiogenesis Affecting Drugs in Oncology 660
8 Compound Strategies at Work: Competitive Benchmarking of Angiogenesis Affecting Cancer Drugs by Compound Strategy 667
8.1 Small Molecules 669
8.1.1 Background 669
8.1.2 Target Strategies of Small Molecule Drugs 670
8.2 Peptide and Protein Drugs 682
8.2.1 Background 682
8.2.2 Target Strategies of Peptide and Protein Drugs 683
8.3 Antibodies 689
8.3.1 Background 689
8.3.2 Target Strategies of Antibody Drugs 689
8.4 Nucleic Acid Therapies 694
8.4.1 Background 694
8.4.2 Target Strategies of Nucleic Acid Drugs 695
8.5 Gene Therapy 697
8.5.1 Background 697
8.5.2 Target Strategies of Gene Therapy Drugs 697
8.6 Drug Delivery and Nanotechnology 700
8.6.1 Background 700
8.6.2 Target Strategies of Reformulated Drugs 700
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets 703
9 Selecting Indication for Angiogenesis Affecting Drugs in Oncology 710
9.1 Acute Lymphocytic Leukemia 713
9.2 Acute Myelogenous Leukemia 714
9.3 Adrenal Cancer 717
9.4 B-cell Lymphoma 718
9.5 Basal Cell Cancer 719
9.6 Biliary Cancer 720
9.7 Bladder Cancer 721
9.8 Bone Cancer 724
9.9 Brain Cancer 725
9.10 Breast Cancer 728
9.11 Cancer (general) 734
9.12 Carcinoid 735
9.13 Cervical Cancer 737
9.14 Chemopreventative 738
9.15 Chronic Lymphocytic Leukemia 739
9.16 Chronic Myelogenous Leukemia 740
9.17 Chronic Myelomonocytic Leukemia 741
9.18 CNS Cancer 741
9.19 Colorectal Cancer 742
9.20 Endometrial Cancer 748
9.21 Fallopian Tube Cancer 750
9.22 Fibro Sarcoma 752
9.23 Gastrointestinal Cancer (general) 753
9.24 Gastrointestinal Stomach Cancer 756
9.25 Gastrointestinal Stromal Cancer 759
9.26 Head and Neck Cancer 761
9.27 Hematological Cancer (general) 764
9.28 Hodgkin's Lymphoma 765
9.29 Kaposi's Sarcoma 766
9.30 Leiomyo Sarcoma 767
9.31 Leukemia (general) 768
9.32 Lipo Sarcoma 769
9.33 Liver Cancer 770
9.34 Lung Cancer (general) 774
9.35 Lymphangioleiomyomatosis 776
9.36 Lymphoma (general) 777
9.37 Mast Cell Leukemia 779
9.38 Mastocytosis 779
9.39 Melanoma 780
9.40 Mesothelioma 784
9.41 Myelodysplastic Syndrome 787
9.42 Myeloma 789
9.43 Nasopharyngeal Cancer 792
9.44 Neuroendocrine Cancer (general) 793
9.45 Neuroendocrine Cancer (pancreatic) 794
9.46 Neurofibromatosis 796
9.47 non-Hodgkin's Lymphoma 797
9.48 Non-Small Cell Lung Cancer 799
9.49 Oesophageal Cancer 805
9.50 Oral Cancer 807
9.51 Osteo Sarcoma 808
9.52 Ovarian Cancer 809
9.53 Pancreatic Cancer 813
9.54 Peritoneal Cancer 816
9.55 Prostate Cancer 818
9.56 Radio/chemotherapy-induced Alopecia 822
9.57 Radio/chemotherapy-induced Infection 822
9.58 Renal Cancer 823
9.59 Sarcoma (general) 828
9.60 Small Cell Lung Cancer 830
9.61 Soft Tissue Sarcoma 833
9.62 Solid Tumor 835
9.63 Squamous Cell Cancer 839
9.64 Synovial Sarcoma 840
9.65 T-cell Lymphoma 841
9.66 Testicular Cancer 842
9.67 Thyroid Cancer 843
9.68 Unspecified 845
9.69 Vaccine adjunct 848
9.70 Waldenstrom's hypergammaglobulinemia 848
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Angiogenesis Affecting Drug Pipeline in Oncology by Investigator 849
10.1 Changes in the Competitive Landscape: MandA, Bankruptcy and Name Change 853
10.2 Company Facts and Ranking 855
10.3 Competitive Fall-Out Assessment 861
10.4 Abbott 864
10.5 Acceleron Pharma 875
10.6 Access 879
10.7 Active Biotech 883
10.8 Adherex 887
10.9 Advantagene 895
10.10 Advaxis 901
10.11 Advenchen 905
10.12 Aeterna Zentaris 909
10.13 Agennix 916
10.14 Aida Pharmaceuticals 920
10.15 Alnylam 924
10.16 Ambit Biosciences 928
10.17 Ambrilia Biopharma 934
10.18 Amgen 938
10.19 Amphora 946
10.20 Angiogen 950
10.21 Angiogenex 954
10.22 Angstrom Pharmaceuticals 958
10.23 Ansaris 962
10.24 Antisoma 966
10.25 Arana Therapeutics 970
10.26 Ariad 974
10.27 Arno Therapeutics 984
10.28 ArQule 988
10.29 Array BioPharma 994
10.30 Astellas 998
10.31 Astex Therapeutics 1004
10.32 AstraZeneca 1008
10.33 Attenuon 1016
10.34 Austrianova 1022
10.35 Bayer 1026
10.36 BioAlliance Pharma 1036
10.37 BioAxone 1041
10.38 Biocad 1045
10.39 Boehringer Ingelheim 1051
10.40 Bolder BioTechnology 1057
10.41 Bristol-Myers Squibb 1063
10.42 BTG 1075
10.43 Cancer Research Technology 1081
10.44 CDG Therapeutics 1085
10.45 Celecure 1089
10.46 Celera 1093
10.47 Celgene 1097
10.48 Cell Therapeutics 1105
10.49 CellCeutix 1110
10.50 Cellmid 1114
10.51 Cephalon 1118
10.52 ChemoCentryx 1122
10.53 Chemokine Therapeutics 1126
10.54 China Sky One Medical 1130
10.55 Choongwae 1134
10.56 Circadian Technologies 1139
10.57 Cue Biotech 1144
10.58 Curis 1148
10.59 Cyclacel 1154
10.60 Cytochroma 1158
10.61 Deciphera Pharmaceuticals 1162
10.62 Dendreon 1166
10.63 Dyax 1170
10.64 Eisai 1174
10.65 Eli Lilly 1181
10.66 EntreMed 1195
10.67 Exelixis 1206
10.68 ExonHit Therapeutics 1218
10.69 Five Prime Therapeutics 1222
10.70 GammaCan 1226
10.71 Genmab 1233
10.72 Gilead Sciences 1240
10.73 GlaxoSmithKline 1247
10.74 GlycoGenesys 1254
10.75 Green Cross 1259
10.76 Hoffmann-La Roche 1264
10.77 Hy BioPharma 1276
10.78 Idera Pharmaceuticals 1280
10.79 ImClone Systems 1287
10.80 ImmunoGen 1292
10.81 ImmuPharma 1296
10.82 Introgen Therapeutics 1300
10.83 Isis Pharmaceuticals 1305
10.84 Johnson and Johnson 1309
10.85 KAI Pharmaceuticals 1317
10.86 Karus Therapeutics 1322
10.87 Kirin Pharma 1326
10.88 Kringle Pharma 1330
10.89 Kyowa Hakko Kirin 1334
10.90 Lee's Pharmaceutical 1340
10.91 Lorus Therapeutics 1344
10.92 MAT Biopharma 1348
10.93 MediGene 1352
10.94 Merck and Co 1358
10.95 Merck KGaA 1362
10.96 Mersana Therapeutics 1369
10.97 MethylGene 1373
10.98 Micromet 1377
10.99 MolMed 1381
10.100 Morvus Technology 1386
10.101 NewSouth Innovations 1390
10.102 Non-industrial Source 1394
10.103 Novartis 1398
10.104 Novelix 1417
10.105 Noxxon 1421
10.106 Oasmia 1425
10.107 Onconova 1429
10.108 OncoTherapy Science 1435
10.109 Oncothyreon 1441
10.110 OSI Pharmaceuticals 1446
10.111 Oxford BioMedica 1451
10.112 OXiGENE 1455
10.113 Pepscan Therapeutics 1461
10.114 PepTx 1468
10.115 Peregrine Pharmaceuticals 1472
10.116 Pfizer 1479
10.117 Pharmacopeia 1499
10.118 PharmaMar 1504
10.119 Pharminox 1510
10.120 Philogen 1514
10.121 PhiloGene 1518
10.122 Pierre Fabre 1522
10.123 Progen 1528
10.124 Protein Sciences 1532
10.125 Protgen 1537
10.126 PTC Therapeutics 1542
10.127 Receptor BioLogix 1549
10.128 Regeneron 1553
10.129 Rexahn 1561
10.130 Rigel 1565
10.131 Sanofi 1569
10.132 Santaris Pharma 1576
10.133 Scancell 1582
10.134 SciClone Pharmaceuticals 1586
10.135 Semafore Pharmaceuticals 1590
10.136 Shionogi 1596
10.137 Simcere Pharmaceuticals 1600
10.138 Spear Therapeutics 1608
10.139 SRI International 1612
10.140 Stainwei Biotech 1618
10.141 SuperGen 1622
10.142 Switch Pharma 1626
10.143 SynDevRx 1630
10.144 Taiho 1634
10.145 Tau Therapeutics 1638
10.146 ThromboGenics 1642
10.147 Tigris Pharmaceuticals 1646
10.148 ToolGen 1650
10.149 TopoTarget 1657
10.150 Tracon Pharmaceuticals 1661
10.151 UCB 1665
10.152 VBL Therapeutics 1672
10.153 Wilex 1676
10.154 Xerion 1682
11 Disclaimer 1686
12 Drug Index 1687
13 Company Index 1697

4.1 List of Figures

Figure 1: Visualization of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 367
Figure 2: The Drug-Target Competitive Landscape of Angiogenesis Affecting Drugs in Oncology - Large Cluster 369
Figure 3: The Drug-Target Competitive Landscape Angiogenesis Affecting Drugs in Oncology - Smaller Clusters 370
Figure 4: Head-to-Head Targeting Competitive Landscape of Angiogenesis Affecting Drugs in Oncology 371
Figure 5: Distribution of Compound Strategies among Angiogenesis Affecting Cancer Drugs 703
Figure 6: Primary Sub-cellular Localization of Drug Targets 704
Figure 7: Number of Companies per Ranking Level 855

4.2 List of Tables

Table 1: Cancer Highlights’™ Five Pillar Drug Assessment 7
Table 2: Breakdown of the Included Angiogenesis Affecting Drug Pipeline in Oncology by Stage of Development 37
Table 3: Head to Head Target Competition among Angiogenesis Affecting Drugs in Oncology 37
Table 4: Overview of Drug Target Strategy Themes 42
Table 5: Terminally Ceased Targets of Angiogenesis Affecting Drugs in Oncology 43
Table 6: Official Gene Name to Target Profle 44
Table 7: Targets of Angiogenesis Affecting Drugs in Oncology Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census 356
Table 8: Identity of Drug Targets with Available Biological Structures 360
Table 9: Number of Target-Target Interactions among Targets of Angiogenesis Affecting Drugs in Oncology 365
Table 10: Available Protein Expression Profiles of Angiogenesis Affecting Drug Targets in Oncology 372
Table 11: Pathway Summary 377
Table 12: Drug Targets without any Identified Assigned Pathways 377
Table 13: Pathway Profiles According to BioCarta of Angiogenesis Affecting Drug Targets in Oncology 379
Table 14: Pathway Profiles According to KEGG of Angiogenesis Affecting Drug Targets in Oncology 397
Table 15: Pathway Profiles According to NetPath of Angiogenesis Affecting Drug Targets in Oncology 417
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness 424
Table 17: Top Competitive Target Strategies of Angiogenesis Affecting Drugs in Oncology 425
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Angiogenesis Affecting Drugs in Oncology 426
Table 19: The Competition Through Close Mechanistic Approximation Between Angiogenesis Affecting Drugs in Oncology in Pre-registration to Marketed 427
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Angiogenesis Affecting Drugs in Oncology 428
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Angiogenesis Affecting Drugs in Oncology 430
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Angiogenesis Affecting Drugs in Oncology 431
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Angiogenesis Affecting Drugs in Oncology 435
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Angiogenesis Affecting Drugs in Oncology 438
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Angiogenesis Affecting Drugs in Oncology 442
Table 26: New and Unique Target Strategies in Preclinical Development of Angiogenesis Affecting Drugs in Oncology 446
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Angiogenesis Affecting Drugs in Oncology 449
Table 28: Target Strategies of No Data, Suspended and Terminated Angiogenesis Affecting Drugs in Oncology 450
Table 29: Connecting Target Strategy with Its Profile Identification Number 454
Table 30: The Competition Through Close Mechanistic Approximation Among Angiogenesis Affecting Drugs in Oncology 660
Table 31: Overview of Compound Strategy Competition Among Angiogenesis Affecting Cancer Drugs 668
Table 32: Overview of the Competitive Landscape of Small Molecule Based Angiogenesis Affecting Cancer Drugs 670
Table 33: Competitive Comparison of Target Strategies of Small Molecule Angiogenesis Affecting Cancer Drugs 671
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Angiogenesis Affecting Cancer Drugs 675
Table 35: Overview of the Competitive Landscape of Peptide Based Angiogenesis Affecting Cancer Drugs 683
Table 36: Competitive Comparison of Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684
Table 37: Pursued Target Strategies of Peptide Based Angiogenesis Affecting Cancer Drugs 684
Table 38: Overview of the Competitive Landscape of Protein Based Angiogenesis Affecting Cancer Drugs 686
Table 39: Competitive Comparison of Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687
Table 40: Pursued Target Strategies of Protein Based Angiogenesis Affecting Cancer Drugs 687
Table 41: Overview of the Competitive Landscape of Antibody Based Angiogenesis Affecting Cancer Drugs 689
Table 42: Competitive Comparison of Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 690
Table 43: Pursued Target Strategies of Antibody Based Angiogenesis Affecting Cancer Drugs 691
Table 44: Overview of the Competitive Landscape of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 695
Table 45: Competitive Comparison of Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696
Table 46: Pursued Target Strategies of Nucleic Acid Based Angiogenesis Affecting Cancer Drugs 696
Table 47: Vectors in Gene Therapy 697
Table 48: Overview of the Competitive Landscape of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 697
Table 49: Competitive Comparison of Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 698
Table 50: Pursued Target Strategies of Gene Therapy Based Angiogenesis Affecting Cancer Drugs 699
Table 51:Overview of the Competitive Landscape of Reformulated Angiogenesis Affecting Cancer Drugs 700
Table 52: Competitive Comparison of Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 701
Table 53: Pursued Target Strategies of Reformulated Angiogenesis Affecting Cancer Drugs 702
Table 54: Compound Strategies based on Sub-Cellular Localization of Angiogenesis Affecting Cancer Drug Targets 704
Table 55 Competitive Summary by Cancer Indication of Angiogenesis Affecting Drugs 711
Table 56: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Lymphocytic Leukemia 713
Table 57: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Acute Myelogenous Leukemia 714
Table 58: The Competition through Close Mechanistic Approximation between Acute Myelogenous Leukemia Drugs 715
Table 59: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Adrenal Cancer 717
Table 60: The Competition through Close Mechanistic Approximation between Adrenal Cancer Drugs 717
Table 61: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of B-cell Lymphoma 718
Table 62: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Basal Cell Cancer 719
Table 63: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Biliary Cancer 720
Table 64: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bladder Cancer 721
Table 65: The Competition through Close Mechanistic Approximation between Bladder Cancer Drugs 722
Table 66: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Bone Cancer 724
Table 67: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Brain Cancer 725
Table 68: The Competition through Close Mechanistic Approximation between Brain Cancer Drugs 727
Table 69: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Breast Cancer 728
Table 70: The Competition through Close Mechanistic Approximation between Breast Cancer Drugs 730
Table 71: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cancer (general) 734
Table 72: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Carcinoid 735
Table 73: The Competition through Close Mechanistic Approximation between Carcinoid Drugs 736
Table 74: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Cervical Cancer 737
Table 75: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chemopreventative 738
Table 76: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Lymphocytic Leukemia 739
Table 77: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelogenous Leukemia 740
Table 78: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Chronic Myelomonocytic Leukemia 741
Table 79: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of CNS Cancer 741
Table 80: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Colorectal Cancer 742
Table 81: The Competition through Close Mechanistic Approximation between Colorectal Cancer Drugs 745
Table 82: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Endometrial Cancer 748
Table 83: The Competition through Close Mechanistic Approximation between Endometrial Cancer Drugs 749
Table 84: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fallopian Tube Cancer 750
Table 85: The Competition through Close Mechanistic Approximation between Fallopian Tube Cancer Drugs 751
Table 86: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Fibro Sarcoma 752
Table 87: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Cancer (general) 753
Table 88: The Competition through Close Mechanistic Approximation between Gastrointestinal Cancer (general) Drugs 755
Table 89: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stomach Cancer 756
Table 90: The Competition through Close Mechanistic Approximation between Gastrointestinal Stomach Cancer Drugs 757
Table 91: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Gastrointestinal Stromal Cancer 759
Table 92: The Competition through Close Mechanistic Approximation between Gastrointestinal Stromal Cancer Drugs 760
Table 93: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Head and Neck Cancer 761
Table 94: The Competition through Close Mechanistic Approximation between Head and Neck Cancer Drugs 763
Table 95: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hematological Cancer (general) 764
Table 96: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Hodgkin's Lymphoma 765
Table 97: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Kaposi's Sarcoma 766
Table 98: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leiomyo Sarcoma 767
Table 99: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Leukemia (general) 768
Table 100: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lipo Sarcoma 769
Table 101: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Liver Cancer 770
Table 102: The Competition through Close Mechanistic Approximation between Liver Cancer Drugs 772
Table 103: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lung Cancer (general) 774
Table 104: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphangioleiomyomatosis 776
Table 105: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Lymphoma (general) 777
Table 106: The Competition through Close Mechanistic Approximation between Lymphoma Drugs 778
Table 107: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mast Cell Leukemia 779
Table 108: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mastocytosis 779
Table 109: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Melanoma 780
Table 110: The Competition through Close Mechanistic Approximation between Melanoma Drugs 782
Table 111: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Mesothelioma 784
Table 112: The Competition through Close Mechanistic Approximation between Mesothelioma Drugs 786
Table 113: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myelodysplastic Syndrome 787
Table 114: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Myeloma 789
Table 115: The Competition through Close Mechanistic Approximation between Myeloma Drugs 790
Table 116: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Nasopharyngeal Cancer 792
Table 117: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (general) 793
Table 118: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neuroendocrine Cancer (pancreatic) 794
Table 119: The Competition through Close Mechanistic Approximation between Neuroendocrine Cancer (pancreatic) Drugs 794
Table 120: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Neurofibromatosis 796
Table 121: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of non-Hodgkin's Lymphoma 797
Table 122: The Competition through Close Mechanistic Approximation between non-Hodgkin’s Lymphoma Drugs 798
Table 123: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Non-Small Cell Lung Cancer 799
Table 124: The Competition through Close Mechanistic Approximation between non-Small Cell Lung Cancer Drugs 802
Table 125: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oesophageal Cancer 805
Table 126: The Competition through Close Mechanistic Approximation between Oesophageal Cancer Drugs 806
Table 127: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Oral Cancer 807
Table 128: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Osteo Sarcoma 808
Table 129: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Ovarian Cancer 809
Table 130: The Competition through Close Mechanistic Approximation between Ovarian Cancer Drugs 811
Table 131: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Pancreatic Cancer 813
Table 132: The Competition through Close Mechanistic Approximation between Pancreatic Cancer Drugs 815
Table 133: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Peritoneal Cancer 816
Table 134: The Competition through Close Mechanistic Approximation between Peritoneal Cancer Drugs 817
Table 135: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Prostate Cancer 818
Table 136: The Competition through Close Mechanistic Approximation between Prostate Cancer Drugs 820
Table 137: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Alopecia 822
Table 138: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Radio/chemotherapy-induced Infection 822
Table 139: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Renal Cancer 823
Table 140: The Competition through Close Mechanistic Approximation between Renal Cancer Drugs 826
Table 141: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Sarcoma (general) 828
Table 142: The Competition through Close Mechanistic Approximation between Sarcoma (general) Drugs 829
Table 143: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Small Cell Lung Cancer 830
Table 144: The Competition through Close Mechanistic Approximation between Small Cell Lung Cancer Drugs 831
Table 145: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Soft Tissue Sarcoma 833
Table 146: The Competition through Close Mechanistic Approximation between Soft Tissue Sarcoma Drugs 834
Table 147: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Solid Tumor 835
Table 148: The Competition through Close Mechanistic Approximation between Solid Tumor Drugs 837
Table 149: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Squamous Cell Cancer 839
Table 150: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Synovial Sarcoma 840
Table 151: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of T-cell Lymphoma 841
Table 152: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Testicular Cancer 842
Table 153: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Thyroid Cancer 843
Table 154: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Unspecified 845
Table 155: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Vaccine adjunct 848
Table 156: Target Strategy Development Profiles of Angiogenesis Affecting Drugs for the Treatment of Waldenstrom's hypergammaglobulinemia 848
Table 157: Competitive Summary by Investigator of Angiogenesis Affecting Drug Development 849
Table 158: Summary Table of Corporate Changes in the Competitive Landscape of Angiogenesis Affecting Drug Development in Oncology 853
Table 159: Example of a Competitive Fall-Out Table (Targeting KDR/Modified) 861
Table 160: Abbott's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 867
Table 161: Acceleron Pharma's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 876
Table 162: Access’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 880
Table 163: Active Biotech's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 884
Table 164: Adherex's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 889
Table 165: Advantagene's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 896
Table 166: Advaxis’Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 902
Table 167: Advenchen's Included Angiogenesis Affecting Drug Pipeline in Oncology and Competitive Fall-Out 906
Table 168: Aeterna Zentaris’Include

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Louis

+1 718 618 4302

Purchase Reports From Reputable Market Research Publishers

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023

  • $ 10 995
  • Industry report
  • July 2014
  • by Global Data

PharmaPoint: Acute Coronary Syndrome - Global Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 7MM in 2013 was $12.3bn, comprised of $5.0bn in branded ...

Analysis of the Global Infectious Disease Diagnostics Market

Analysis of the Global Infectious Disease Diagnostics Market

  • $ 10 000
  • Industry report
  • September 2014
  • by Frost & Sullivan

Molecular Methods Present Significant Opportunities This deliverable provides research and analysis of the global infectious disease diagnostics market. It includes an in-depth analysis of revenue forecast ...

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation

  • $ 6 995
  • Industry report
  • July 2014
  • by GBI Research

Frontier Pharma: Breast Cancer - Identifying and Commercializing First-in-Class Innovation Summary Exceptionally Large and Innovative Pipeline The breast cancer pipeline is the largest in the pharmaceutical ...

Bcc Research Bitopertin Forecast

August 2014 $ 5 500

6 Companies

Company Profiles

DexCom Inc.

United States

NeuroMetrix Inc.

United States

Pfizer Inc.

United States

Medtronic Inc.

United States

Medtronic MiniMed Inc.

United States

ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.